These data indicate ICOSL vIgD-Fc can protect animals from development of GvHD in this human PBMC-mouse model, and that the activity of the most potent antagonist ICOSL vIgD-Fc tested (A2237) is more protective than belatacept in this model. Here, ICOSLG is linked to graft versus host disease.